Figure 1.
Flow of patients from referral to initiation of long-acting injectable (LAI)-cabotegravir/rilpivirine (CAB/RPV) for human immunodeficiency virus (HIV)-1 treatment as part of enrollment into the LAI pilot program. ADAP, AIDS Drug Assistance Program; IDP, Grady Ponce de Leon Center; NNRTI, nonnucleoside reverse-transcriptase inhibitor; RNA, ribonucleic acid.